Eli Lilly, Johnson & Johnson Innovation – JJDC, Pfizer Ventures and Alexandria Venture Investments all returned for the $26m second tranche of the immunobiology therapy developer’s series A round.

US-based immunology therapeutics developer TRexBio added $26m to close an $85m series A round featuring pharmaceutical firms Eli Lilly, Johnson & Johnson and Pfizer on Tuesday.

Investment firm Polaris Partners led the extension, which included Eli Lilly and corporate venturing units Johnson & Johnson Innovation – JJDC and Pfizer Ventures.

The second tranche was filled out by the venture capital subsidiary of life sciences real estate investment trust Alexandria Real Estate Equities, as well as investment firm Laurion Capital and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn